Northern Trust Corp Cyteir Therapeutics, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.84 - $3.13 $96,826 - $106,714	34,094 Added 99.72%	68,283 $207,000
Q3 2023 Nov 13, 2023	BUY	$2.71 - $2.84 $41,205 - $43,182	15,205 Added 80.09%	34,189 $97,000
Q1 2023 May 15, 2023	BUY	$1.47 - $1.84 $5,993 - $7,501	4,077 Added 27.35%	18,984 $34,000
Q4 2022 Feb 13, 2023	BUY	$1.18 - $1.76 $2,043 - $3,048	1,732 Added 13.15%	14,907 $24,000
Q2 2022 Aug 12, 2022	SELL	$1.62 - $4.4 $202,611 - $550,303	-125,069 Reduced 90.47%	13,175 $39,000
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $223,126 - $691,757	65,819 Added 90.88%	138,244 $521,000
Q4 2021 Feb 08, 2022	SELL	$9.83 - $19.21 $7,451 - $14,561	-758 Reduced 1.04%	72,425 $823,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $1.07 Million - $1.6 Million	73,183 New	73,183 $1.28 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.